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Background.Lowexpressionorabsenceofdendriticcell(DC)surfaceB7moleculescaninduceimmunetoleranceorhyporesponse.
Whether DCs could induce indirect allogeneic-speciﬁc cross-tolerance or hyporesponse to recipient T cells remains unclear.
Methods. Generated from C3H/He mice bone marrow cells pulsed with donor antigen from C57BL/6 mice, recipient DCs were
incubated with B7 antisense peptide (B7AP). Immune regulatory activities were examined in vitro by a series of mixed lymphocyte
reactions. Murine allogeneic carotid artery orthotopic transplantation was performed from C57BL/6 to C3H/He. Recipients were
given B7AP-treated DCs 7 days before transplantation. Allograft pathological analysis was done 2 months after transplantation.
Results. B7AP-pretreated DCs markedly inhibited T-cell proliferation compared with untreated group. Pretreated T cells exhibited
markedly reduced response to alloantigen versus third-party antigen. Pathological analysis of arterial allografts demonstrated
signiﬁcant reduction of intimal hyperplasia in B7-AP pretreated group versus control. Conclusion. Blockade of B7 molecules
by B7AP could induce indirect allogeneic-speciﬁc hyporesponse and inhibit arterial allograft intimal hyperplasia, which may be
involved in future strategies for human allograft chronic rejection.
1.Introduction
Graft loss from chronic rejection has become the major
obstacle to the long-term success of whole organ transplan-
tation [1]. It is accepted that direct and indirect recognitions,
both mediated by donor and recipient dendritic cells (DCs),
arethemajorcausesforalltypesoforgantransplantrejection
[2, 3]. The direct activation of T lymphocytes by donor-
derived antigen-presenting cells (APCs) is thought to be
responsible for the vigor of acute rejection, while the indirect
allorecognition has been implicated in the initiation of
chronic allograft dysfunction [4–6].
The B7-CD28/CTLA4 costimulatory pathway plays a
crucial role in the regulation of T-cell activation [7]. B7
molecules are expressed on the surface of APCs, providing a
critical co-stimulatory signal to T cells by engaging CD28.
Blockade of the B7-CD28 interaction in vitro can generate
antigen-speciﬁc anergy [8–10]. Administration of mono-
clonal antibodies (MoAbs) against B7 or CTLA4-Ig fusion
protein to block B7 has been shown to be promising as
a treatment for allograft rejection [11–13]. It has been
reported that the recipients immunized with donor resting
B cells or immature DCs could induce speciﬁc immune
tolerance and prolong allograft survival. This eﬀect has been
attributed to low-level expression or absence of B7 molecules
on these cells [14, 15]. Although recent studies [16–18]h a v e
shown that modiﬁed or pretreated DCs can induce direct
alloreactive T-cell hyporesponsiveness, it is not yet clear
whether DCs can also induce indirect allogeneic-speciﬁc
cross-hyporesponsiveness to recipient T cells. Recent years
have witnessed an increasing interest in the development
of nonimmunogenic peptide as an antagonist for protein-
protein interaction in immunomodulatory therapeutics [19,
20]. Progress in antisense technology and molecular mod-
eling over the past decade has made molecular recognition
study possible [21–23]. Antisense peptides are short peptide
sequences that speciﬁcally constitute one side of the binding
sites of complementary protein pairs [24]. B7 antisense
peptide (B7AP) is a peptide analogue of the CD28-binding
region [12, 24]. It is characterized by higher aﬃnity to B72 Clinical and Developmental Immunology
ligand, lower molecular weight, and lower immunogenicity
and diﬃculty to be metabolized compared with CTLA4-Ig
[12, 25] which would block the allorecognition in a longer
period to take more eﬀect. It has been reported [12] that
blockade of B7 molecules on donor splenocytes pretreated
with B7AP could induce speciﬁc immune hyporesponse and
prolong allograft survival in the recipients. In this study,
we tried to induce cross-hyporesponsiveness to recipient T
cellsinanindirectpathwaybyB7APpretreateddonor-pulsed
recipient DCs. The results showed that the administration of
this recipient DCs could induce indirect allogeneic-speciﬁc
cross-hyporesponsiveness to recipient T cells and inhibit the
intimal thickening of arterial allograft, which may lead to the
suppression of allograft chronic rejection.
2.MaterialsandMethods
2.1.Animals. C57BL/6(H-2Kb),C3H/He(H-2Kk)andB ALB/
C(H-2Kd)malemiceweighing29–32g,8–12weeksold,were
purchased from Shanghai Laboratory Animal Center of Chi-
neseAcademyofSciences(Shanghai,China),maintainedina
speciﬁcpathogen-freefacilityatFudanUniversity(Shanghai,
China). All animal surgical procedures were approved by
the Institutional Animal Care and Use Committee of Fudan
University.
2.2. Synthesis and Puriﬁcation of B7AP [26]. Antisense
peptides were synthesized and puriﬁed by GL Biochem
Ltd., (Shanghai). It has been reported that the MYPPPY
motif is the core of CD28 binding sites to its ligand B7.
Several diﬀerent peptides containing the motif were screened
by BIOPOLYMER and BINDING SITE ANALYSIS in the
INSIGHT II molecular modeling software package, and
B7AP was obtained with the sequence EFMYPPPYLD. The
peptide was synthesized on a solid phase peptide synthesizer
(Multiple Peptide Synthesizer; Genemed Synthesis, Inc., CA,
USA). The crude peptide was puriﬁed by the Varian Prostar
high performance liquid chromatography (HPLC) system
using a C8 column (Varian Prostar HPLC system, CA,
USA). Analytical HPLC was performed through a Varian
C8 analytical column using a linear gradient of 0–100%
acetonitrile in water containing 0.1% triﬂuoroacetic acid
over a period of 20min. The identity of the peptide was
conﬁrmed by mass spectrometry (Voyager Elite model,
Perceptive Bio system, Applied Bio systems, WA, USA). The
purity of the peptide (higher than 95%) was examined
by HPLC analysis. Peptide was lyophilized and stored at
−20◦C. Serum-free RPMI 1640 was added to adjust the
concentrations of B7AP before use.
2.3. Preparation of the Donor Antigen. Freshly harvested
C57BL/6 mice spleens were ﬁrst minced in 2mL complete
RMPI-1640 medium, ﬁltered through a nylon mesh, and
then transferred into a 15-mL centrifugal tube. After cen-
trifugation at 1500rpm for 5min followed by discarding of
thesupernatant,completeRPMI-1640mediumwasaddedto
the splenocyte suspension. The suspension was then trans-
ferred to another centrifugal tube containing 3mL lympho-
cyte separation medium and centrifuged at 2000rpm for
20min to get the lymphocyte layer. Then the lymphocyte
layer was carefully transferred to another centrifugal tube,
added with complete RPMI 1640 medium and centrifuged
again at 1500rpm for 5min. After discarding the super-
natant, complete RPMI 1640 medium was added and the
cell concentration was adjusted to 1 × 106/mL to get the
pure lymphocyte suspension. Lymphocyte suspension (1 ×
106/mL) was frozen at −80◦C (or liquid nitrogen) and
thawed at 37◦C for 6 times, then centrifuged at 7500rpm
for 10min. The supernatant was harvested, ﬁltered through
0.22μm membrane, and stored at 4◦C.
2.4. Propagation of Bone-Marrow-Derived DCs Loaded with
Donor Antigen. Bone-marrow-derived dendritic cells (BM-
DCs) were generated as previously described [27, 28]w i t h
some modiﬁcation. Bone marrow cells harvested from the
femurs and tibias of C3H/He mice were cultured in 24-well
plates (1 × 106 cells per well). Culture medium contains
160U/mL gentamycin, 2mmol/L L-glutamine, 0.05mmol/L
2-mercaptoethanol, 1mmol/L sodium pyruvate, and 10%
(v/v) FCS (Gibco, Gaithersburg, MD, USA) in the presence
of recombinant mouse granulocyte macrophage colony-
stimulating factor (rmGM-CSF,10μg/mL; R&D Systems,
Minneapolis, MN, USA). All cultures were incubated at
37◦C with 5% humidiﬁed CO2. Nonadherent cells would
be released spontaneously from proliferating clusters after
48 hours of culture. Medium change containing rmGM-
CSF was done every two days. In the sixth day, the donor
antigen and recombinant mouse TNF-α (rmTNF-α,5 0μg/L;
R&D Systems, Minneapolis, MN, USA) were added to
the medium. In the eighth day, the buoyant cells were
harvested at the concentration of 1 × 106 cells/mL. DCs
were irradiated with 3000 rads γ-ray and then incubated
with B7AP (10mg/L) at 37◦C for 90min. After washing
with phosphate buﬀered saline (PBS) once, tolegenic DCs
were modulated at the concentration of 3 × 106/mL. The
purity of DC preparations was routinely monitored by ﬂow
cytometric analysis using anti-CD11c monoclonal antibody
(eBioscience, San Diego, CA, USA). This DC preparation
protocol could enrich CD11c + cells more than 85%.
2.5. Flow Cytometry. Cell-surface phenotypic analysis of
B7AP-treated DCs was done by EPICS ELITE ﬂow cytometer
(Coulter, Hialeah, FL, USA). Fluorescein-isothiocyanate-
(FITC-) conjugated antimouse MHC Class II, CD80 and
CD86 antibody (anti-MHC Class II-FITC, anti-CD80-FITC,
anti-CD86-FITC) were used for cell staining (BD PharMin-
gen, San Diego, CA, USA). FITC-conjugated isotype-
matched irrelevant monoclonal antibodies (rat IgG2b,
Armenian hamster IgG2, and rat IgG2a, resp.) were used as
negative controls (Cedarlane Laboratories, Hornby Ontario,
Canada).
2.6. Mixed Lymphocyte Reaction (MLR). T cells prepared
from recipient splenocytes by nylon wool puriﬁcation were
used as responders (2.5 × 106/mL). B7AP-treated recipient
DCs(0.5 × 106 fromC3H/Hemice)wereusedasstimulators
and irradiated with 3000 rads before use. Untreated recipient
DCs pulsed with donor antigen and recipient DCs withoutClinical and Developmental Immunology 3
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Figure 1: BM-DCs detected by inverted microscope and scanning electron microscope. Progenitor cells were propagated in the presence of
rmGM-CSF. After TNF-α and donor antigen addition, the cells show signiﬁcant diﬀerentiation with typical DC appearance under inverted
microscope (a) and scanning electron microscope (b) and (c).
donorantigenwereincludedascontrols.B7APwasdilutedto
4 ×102 mg/L, 4 × 101 mg/L, 4 × 100mg/L,4 × 10
−1 mg/L,
4 × 10
−2mg/L, 4 × 10
−3 mg/L, 4 × 10
−4 mg/L, and 4 ×
10
−5 mg/L by serum-free RPMI 1640 and then incubated
with recipient DCs (0.05mL DCs and 0.05mL B7AP) for
1h o u ra t3 7 ◦C. After that, MLR between DCs and T cells
was performed. Cultures were established in triplicate in
96-well round-bottom microculture plates (200μLp e rw e l l )
and maintained in complete medium for 7 days in 5%
CO2 at 37◦C. 3[H] TdR (1μCi/well) was added in the ﬁnal
18hrs. Cells were harvested onto glass ﬁber disks using an
automatedsystem,andincorporationof 3[H]TdRintoDNA
was assessed by Wallac 1450 Microbeta liquid scintillation
counter. Data was presented as mean counts per minute
(cpm) ±SD in triplicate replication.
2.7. Induction of Indirect Allogeneic-Speciﬁc Hyporesponse to
RecipientT cells In Vitro . Mixedlymphocytereaction(MLR)
between recipient T cells and B7AP-pretreated recipient
DCs pulsed with donor antigen was performed in complete
medium for 72hrs in 5% CO2 at 37◦C. Then PBS was added
and the suspension was harvested by centrifugalization
at low rotation speed (500r/m × 15min) to remove the
precipitated dead cells. After being washed for three times by
PBS,thepretreatedTcellswereadjustedattheconcentration
of 5 × 106/mL and placed in static condition for 24hrs.
For the second round of MLR, the pretreated T cells were
used as responders (2.5 × 105 per well). The recipient DC
pulsed with donor antigen untreated by B7AP was used as
stimulators (0.5 × 105 per well). The recipient DC pulsed
with the third party donor (derived from BALB/C) without
B7AP treatment and the recipient DC without donor antigen
were included as controls. Cell harvesting and thymidine
incorporation was performed the same way as the ﬁrst round
of MLR.
2.8. Murine Model of Allogeneic Carotid Artery Orthotopic
Transplantation. Both C3H/He-recipient mice and C57BL/6
donormicewereanesthetizedwithketamine(75mg/kg,i.p.),
had their hair shaved, and then placed in a supine position
with their limbs immobilized. The skin of the operative
region was sterilized. Longitudinal incisions from the right
mandibular angle to the middle point of the right clavicle
were made for both donor and recipient surgeries. Common
carotid artery of the donor was dissected, excised for a
0.5cm segment, and then ﬂushed and stored at 4◦C Ringer’s
solution. After the dissection and removal of a 0.5cm
segment of recipient carotid artery, the arterial graft was
anastomosed to the recipient carotid artery orthotopically
using an end-to-end interrupted suture technique with 10-
0 PROLENE at 40x magniﬁcation. The distal end of the
carotid was ﬁrst reperfused, followed by the reperfusion of
the proximal end under the condition of no anastomotic
bleeding. The incision was closed with layered sutures.
Animals were allowed access to food and water right after
surgery.
To assess the eﬀect of the pretreated DCs on the
intimal hyperplasia of the arterial graft, recipient mice
(n = 10) were given 3 × 106 cells intravenously via the
femoral vein, 7 days before transplantation in the absence
of immunosuppression. Meanwhile, control group (n = 10)
were established without any treatment. Arterial grafts were
harvested for histopathological examination 2 months after
transplantation.
2.9. Morphometric and Histological Analysis. Cross sections
of arterial grafts were ﬁxed in 10% formaldehyde and
then embedded into paraﬃn and stained with hematoxylin
and eosin. The area of the tunica intima and tunica
media was assessed by light microscopy and computer-based
Morphometric Analysis System. Only vessels that were cut
orthogonally and displayed a clear internal and outer elastic
lamina were accepted. The thickness of tunica intima was
calculated by the following equation: Thickness of tunica
intima = Area of tunica intima/(Area of tunica intima + Area
of tunica media) [29].
2.10. Statistical Analysis. All data are presented as means
± SD. Statistical analysis was performed by STATA version
8.0. Homoscedasticity analysis and t test were used to4 Clinical and Developmental Immunology
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Figure 2: Expression of MHC-II (I-Ak) and B7 molecules (CD80/86) on BM-DCs. The expression of B7 or MHC-II by the indicated cell
fractions is represented by ﬁlled histograms (black). The open histograms (grey) represent control staining with an isotype control antibody.
Flow cytometric analysis demonstrated that over 55% of the cells express MHC-II (I-Ak) molecule (a), while 80 + % of the cells expressed
B7.1 (CD80) and B7.2 (CD86) molecules (b) and (c). One representative of three independent experiments is shown.
analyze the signiﬁcance of diﬀerences between groups for
the proliferative response of T cells and the thickness of
the arterial intima. P value less than 0.05 was considered as
statistically signiﬁcant.
3. Results
3.1. Propagation of Murine Recipient BM-DCs Loaded with
Donor Antigen. A large number of progenitor cells were
propagated in the presence of rmGM-CSF. After TNF-
α was added in the medium, the cells show signiﬁcant
diﬀerentiation with typical DC appearance [30]( Figure 1)
under inverted microscope and scanning electron micro-
scope. Majority of the progenitor cells diﬀerentiated to DCs
as MHC-II (I-Ak) molecule are expressed on 55 + % of the
cells by ﬂow cytometric analysis and 80 + % of the cells
expressed B7(CD80,CD86) molecules (Figure 2).
3.2. Inhibition of T-cell Proliferative Response Using B7AP
Pretreated DCs. In order to ﬁnd the concentration of B7AP
that can maximally block B7 molecules, DCs were incubated
withB7APatvariousconcentrations,andthenMLRbetween
DCs and T cells was performed. B7AP could inhibit the
proliferative response of T-cells compared with untreated
group(P<0.05, Table 1) and perform the maximal blockage
at the end-point concentration of 10mg/L (Figure 3(a)).
Furthermore, to test the speciﬁcity of the inhibitory eﬀect
of B7AP, a control peptide (FTD10) was synthesized andClinical and Developmental Immunology 5
Table 1: MLR of T cells and recipient DCs with diﬀerent treatment.
Groups Final concentration of B7AP Cpm
B7AP-pretreated
C57BL/6aC3H/HeDCs+T cells
Subgroup 1 100mg/L 252 ±40
Subgroup 2 10mg/L 236 ±36
Subgroup 3 1mg/L 2239 ±316
Subgroup 4 1 ×10
−1 mg/L 2197 ±777
Subgroup 5 1 ×10
−2 mg/L 2097 ±150
Subgroup 6 1 ×10
−3 mg/L 2039 ±210
Subgroup 7 1 ×10
−4 mg/L 1935 ±79
Subgroup 8 1 ×10
−5 mg/L 2070 ±208
Untreated
C57BL/6C3H/HeDCs+T cells 0 2106 ±326
DCs without donor antigen + T cells 0 252 ± 125
T cells alone 0 124 ±35
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Figure 3: B7AP-pretreated DCs inhibited T-cell proliferation in MLR. Under high concentrations of B7AP (100mg/L), T cells demonstrated
a low proliferation capacity. However, proliferation of T cells surged to a rather high level when the ﬁnal concentration of B7AP went down
from 10mg/L to 1mg/L, followed by a plateau (a), indicating that B7AP ﬁnal concentration of 10mg/L could ensure maximal blockage of
DCs u r f a c eB 7m o l e c u l e s .T h eB M - DC sw e r ep r e t r e a t e db yt h eB 7 A Pa n dc o n t r o lp e p t i d ea tt h es a m ec o n c e n t ra t i o n( 1 0m g / L ) ,a n dt h eM L R
was performed as described above (b). NS: normal saline group, MYPPPY group: relative peptide, FTD10 (FTDSVRDPKT) group: negative
control peptide.
the MLR was performed at the same concentration of B7AP
(10mg/L).Arelativepeptide,MYPPPY,wasalsotestedforits
inhibitory eﬀect in the MLR at the concentration of 10mg/L.
As shown in Figure 3(b), all groups have signiﬁcant
diﬀerences compared to the B7AP group (P<0.05).
The FTD10 control group showed no signiﬁcant diﬀerence
compared to the normal saline (NS) group (2087 ± 150
versus 2102 ± 101, P>0.05). The relative peptide MYPPPY
showed a certain extent of inhibitory eﬀect, but also with no
signiﬁcant diﬀerence compared to the NS group (1480±130
versus 2087±150, P>0.05). The data demonstrated that the
inhibitory eﬀect of B7AP was speciﬁc (Figure 3(b)).
3.3. Induction of Alloantigen-Speciﬁc T-cell Hyporesponsive-
ness Using B7AP Pretreated DCs. The proliferative response
of T cells was examined in secondary MLR, which has shown
that T cells harvested from the primary MLR exhibited
markedly reduced responses to alloantigen (C57BL/6) versus6 Clinical and Developmental Immunology
(a) (b) (c) (d)
Figure 4:HEstainedsectionsofthearterialgrafts2monthsaftertransplant.(a)nativecarotidartery;(b)carotidarterialallograft(untreated
control);(c)carotidarterialallograft(pretreated);(d)zoomed-inpictureofthesquarefragmentinFigure 4(b).GraftsinbothDC-pretreated
a n dc o n t r o lg r o u ps h o w e dd i ﬀused and concentric intimal thickening compared with normal nontransplanted artery (a), which is the main
feature of chronic allograft rejection. However, the intima was signiﬁcantly thinner in the pretreated group (c) than that in the control group
(b). Also we could see more lymphocytes inﬁltrated within control group allografts (d).
Table 2: MLR of pretreated T cells and recipient DCs pulsed with
diﬀerent donor antigen.
Groups Cpm values
Pretreated T cells +
C57BL/6C3H/He DC 355 ±46
Pretreated T cells +
BALB/CC3H/He DC 2230 ±248
Control 105 ±22
C57BL/6C3H/HeDC:RecipientDCspulsedwithdonorantigen(derivedfrom
C57BL/6).
BALB/6C3H/HeDC: Recipient DCs pulsed with the third party antigen
(derived from BALB/C).
the third party unrelated antigen (BALB/C), indicating
B7AP pretreated DCs could induce alloantigen-speciﬁc T-
cell hyporesponsiveness. (P<0.05, Table 2).
3.4. Inhibition of Arterial Allograft Intimal Hyperplasia. A
total of 20 transplants were performed with the surgical
successful rate of 100%. All mice and arterial grafts survived
2 months. The arterial grafts were examined under micro-
scope 2 months after transplantation, and three histologic
sections of every allograft were analyzed. During specimen
harvesting, arterial grafts in the pretreated group presented
stronger pulse compared to the control group. In all arterial
grafts, histopathological examination demonstrated diﬀused
and concentric intimal thickening compared to the normal
nontransplanted artery, which involves the entire circumfer-
enceofthevesselwithachronicpictureat2month.However,
the mean intimal thickness was signiﬁcantly reduced in the
pretreated group compared to the control group (mean
intimalthickness:0.071±0.03 versus0.179±0.056,P<0.05,
Figure 4).
4. Discussion
In the ﬁeld of organ transplantation, it is accepted that both
donor and recipient DCs mediate the allograft rejection.
Therecognitionofforeignmajorhistocompatibilitycomplex
(MHC) molecules by recipient alloreactive T-cells via two
distinct pathways, “direct” (donor DCs presenting donor
MHC molecules) and “indirect” (recipient DCs presenting
donor MHC molecules), is one of the major causes of
diﬀerent types of organ transplant rejection [2, 3]. It has
been suggested that the direct pathway predominates during
early acute rejection and the indirect pathway provides a
continuous supply of alloantigen responsible for chronic
rejection later [4, 5]. Animal trials found that blocking
the direct allorecognition pathway only did not attain
allograft tolerance, which indicates that maintaining long-
term clinical transplantation tolerance by arresting the
indirect pathway is essential [3]. In addition, administration
of donor-derived dendritic cells (DCs) to prevent allograft
rejection is not applicable for clinical use. We therefore
attempted to explore the use of recipient-derived DCs pulsed
with donor antigens via the indirect pathway.
T-cell activation is a process involving alloantigen recog-
nition and costimulatory signaling. Besides the interaction
of the TCR and MHC-antigen complex, a productive
immune response and maintenance of T-cell homeostasis
are determined largely by co-stimulatory molecules [31].
Co-stimulatory molecule-deﬁcient DCs have the capacity to
control immune responses and induce T anergy [25, 32]. It
would result in the alloantigen-speciﬁc T hyporesponse. The
most active pathway of costimulation is the interaction of
CD28 receptor and B7 ligands [7].
Aortic allotransplantation in mice is a useful experimen-
tal model to study the mechanisms of chronic rejection in
allotransplantation [33–35]. However, the application of the
conventional aortic model is limited by a high morbidity and
technically diﬃcult to perform. So we developed a new sim-
ple method of carotid artery orthotopic allotransplantation
inmice.Thisnewprocedureiseasytocarryoutandhasalow
morbidity after extensive training based on our experience.
Compelling evidence that induction of tolerance in the
indirectpathwayfavorsgraftsurvivalcamefromexperiments
in which blockade of CD28-B7 by monoclonal antibodies
(MoAbs) against B7 or CTLA4-Ig could produce indeﬁnite
allograft survival [36]. Antisense peptides are short peptide
sequences that speciﬁcally constitute one side of the binding
sites of complementary protein pairs [24]. B7AP is a peptideClinical and Developmental Immunology 7
analogue of the CD28-binding region [26, 37], which can be
characterized by higher aﬃnitytoB7ligand,lowermolecular
weight,andlowerimmunogenicityanddiﬃculttobemetab-
olized compared with CTLA4-Ig [26, 38]. It would block
the allorecognition in a longer period to take more eﬀect.
Chen et al. reported [26] that blockade of B7 molecules on
donor splenocytes with B7AP could induce speciﬁc immune
hyporesponse and prolong allograft survival in the recipi-
ents. Our study also conﬁrmed that B7AP could inhibit the
T-cell proliferative response stimulated by DCs. Transient
blockade of B7-CD28 (using CTLA4Ig) did not abrogate
the development of the intimal hyperplasia [3, 39]. It was
uncertain whether more stable blockade of the indirect
allorecognition would be more eﬀective to inhibit intimal
thickening in carotid artery allotransplantation. Using B7AP
can lead to a stable blockade of CD28-B7 costimulation
by virtue of its characters. The result found recipient BM-
DCs pulsed with donor antigen and pretreated by B7AP
could induce recipient T-cell-speciﬁc hyporesponse to the
donor antigen in vitro and signiﬁcantly alleviate the intimal
thickening in the murine allotransplantation, which is a key
manifestation of chronic rejection. It indicates that an ap-
proach to use recipient DCs as a “vaccine” strategy provides
a feasible approach to inhibit the chronic rejection in organ
transplantation.
5. Conclusion
Our research has demonstrated that blockade of B7/
CD28 costimulatory pathway by B7AP in the indirect al-
lorecognition could induce allogeneic-speciﬁc cross-hypore-
sponsiveness and inhibit the arterial allograft intimal hyper-
plasia due to chronic rejection, which may be involved in
future strategies for human allograft chronic rejection.
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